Drug Trial Radar · NCT07286266
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jun 18, 2026
Primary completion
Jul 22, 2030
Study completion Jul 22, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GOG, ENGOT, APGOT
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
Conditions
- Ovarian Neoplasms
Interventions
Mocertatug rezetecanDrug
Mocertatug rezetecan will be administered
PaclitaxelDrug
Paclitaxel will be administered
Pegylated liposomal doxorubicin (PLD)Drug
PLD will be administered
TopotecanDrug
Topotecan will be administered
GemcitabineDrug
Gemcitabine will be administered
PembrolizumabDrug
Pembrolizumab will be administered
BevacizumabDrug
Bevacizumab will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by BICRTime frame: Up to approximately 212 weeks
- Overall Survival (OS)Time frame: Up to approximately 212 weeks
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Randwick, New South Wales, Australia · Recruiting
GSK Investigational Site
Auchenflower, Queensland, Australia · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Fukuoka, Japan · Recruiting
GSK Investigational Site
Fukuoka, Japan · Recruiting
GSK Investigational Site
Hokkaido, Japan · Recruiting
GSK Investigational Site
Hyōgo, Japan · Recruiting
GSK Investigational Site
Kanagawa, Japan · Recruiting
GSK Investigational Site
Kanagawa, Japan · Recruiting
GSK Investigational Site
Mie, Japan · Recruiting
GSK Investigational Site
Okinawa, Japan · Recruiting
GSK Investigational Site
Osaka, Japan · Recruiting
GSK Investigational Site
Saitama, Japan · Recruiting
GSK Investigational Site
Tottori, Japan · Recruiting
GSK Investigational Site
Gyeonggi-do, South Korea · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
GSK Investigational Site
Suwon Kyunggi-do, South Korea · Recruiting
GSK Investigational Site
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
GSK Investigational Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.